Radium-223Designed with the goal of preventing or slowing the spread of the cancer to the bones, not to cure the cancer, Radium-223 is a new treatment option for men with metastatic prostate cancer whose cancer has spread despite receiving medical or surgical therapy to lower testosterone.
Who is a Candidate for Radium-223?
Radium-223 is an alternative for men diagnosed with metastatic prostate cancer who are too ill to undergo chemotherapy. Not only are patients’ life expectancies increased by an average of about three months, Radium-223 also improves their quality of life by offering pain relief.
What to Expect From Radium-223
Radium-223 is administered intravenously over a one minute period, and is usually given once every four weeks for a maximum of six treatment sessions. The radiation is focused and precise, minimizing the damage to other tissue and allowing patients to return home shortly after receiving the injection.
Why Choose John Theurer Cancer Center for Radiation Therapy
We have a history of leading radiation therapy in New Jersey. The Department of Radiation Oncology at John Theurer Cancer Center at Hackensack University Medical Center was the first center in the state to offer stereotactic radiosurgery (a non-surgical option) for the treatment of brain tumors.
We were also the first medical center in New Jersey to offer TrueBeam® image-guided radiation therapy, a radically different approach to treating even the most challenging cancers with unprecedented speed and accuracy. This technology is now offered throughout the network.
John Theurer Cancer Center has affiliate locations across the state, providing you with access to advanced radiation therapy options conveniently located close to home.
The cancer surgeons at John Theurer Cancer Center perform more minimally invasive cancer surgeries than any other center in New Jersey.
We have numerous radiation oncologists available throughout New Jersey.